DK0778888T3 - Antigen-mærket ikke-infektiös retroviruslignende partikel - Google Patents

Antigen-mærket ikke-infektiös retroviruslignende partikel

Info

Publication number: DK0778888T3
Authority: DK; Denmark
Prior art keywords: pct; gene product; hiv; antigenic marker; marker
Prior art date: 1994-08-15

Application number

DK95927611T

Other languages

English (en)

Inventor

Benjamin Rovinski

Fei-Long Yao

Shi-Xian Cao

Roy Persson

Michel H Klein

Original Assignee

Sanofi Pasteur Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-15

Filing date

1995-08-15

Publication date

2006-10-23

1995-08-15 Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd

2006-10-23 Application granted granted Critical

2006-10-23 Publication of DK0778888T3 publication Critical patent/DK0778888T3/da

Links

208000015181 infectious disease Diseases 0.000 title abstract 4
230000002458 infectious effect Effects 0.000 title abstract 3
239000002245 particle Substances 0.000 title abstract 3
239000000427 antigen Substances 0.000 title 1
102000036639 antigens Human genes 0.000 title 1
108091007433 antigens Proteins 0.000 title 1
239000003550 marker Substances 0.000 abstract 6
230000000890 antigenic effect Effects 0.000 abstract 5
101710177291 Gag polyprotein Proteins 0.000 abstract 2
241000723873 Tobacco mosaic virus Species 0.000 abstract 2
101710132601 Capsid protein Proteins 0.000 abstract 1
101710094648 Coat protein Proteins 0.000 abstract 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 abstract 1
208000031886 HIV Infections Diseases 0.000 abstract 1
208000037357 HIV infectious disease Diseases 0.000 abstract 1
101710125418 Major capsid protein Proteins 0.000 abstract 1
101710141454 Nucleoprotein Proteins 0.000 abstract 1
101710083689 Probable capsid protein Proteins 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
230000036436 anti-hiv Effects 0.000 abstract 1
108700004025 env Genes Proteins 0.000 abstract 1
101150030339 env gene Proteins 0.000 abstract 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
238000003780 insertion Methods 0.000 abstract 1
230000037431 insertion Effects 0.000 abstract 1
108010089520 pol Gene Products Proteins 0.000 abstract 1
230000003362 replicative effect Effects 0.000 abstract 1
230000001177 retroviral effect Effects 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Public Health (AREA)
General Physics & Mathematics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Veterinary Medicine (AREA)
Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)

DK95927611T 1994-08-15 1995-08-15 Antigen-mærket ikke-infektiös retroviruslignende partikel DK0778888T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/290,105 US5955342A (en)	1994-08-15	1994-08-15	Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region

Publications (1)

Publication Number	Publication Date
DK0778888T3 true DK0778888T3 (da)	2006-10-23

Family

ID=23114550

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95927611T DK0778888T3 (da)	1994-08-15	1995-08-15	Antigen-mærket ikke-infektiös retroviruslignende partikel

Country Status (12)

Country	Link
US (5)	US5955342A (da)
EP (1)	EP0778888B1 (da)
JP (2)	JP3871708B2 (da)
AT (1)	ATE331026T1 (da)
AU (1)	AU704309B2 (da)
CA (1)	CA2197446A1 (da)
DE (1)	DE69535075T2 (da)
DK (1)	DK0778888T3 (da)
ES (1)	ES2268693T3 (da)
MX (1)	MX9701149A (da)
PT (1)	PT778888E (da)
WO (1)	WO1996005292A1 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6080408A (en) *	1994-08-22	2000-06-27	Connaught Laboratories Limited	Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
AU702802B2 (en)	1994-10-18	1999-03-04	Scottish Crop Research Institute	Method of producing a chimeric protein
WO1996030523A2 (en) *	1995-03-31	1996-10-03	Hans Wolf	Antigen presentation system based on retrovirus-like particles
GB9607899D0 (en) *	1996-04-17	1996-06-19	Scottish Crop Research Inst	Virus-like particle
US6602505B2 (en)	1998-04-30	2003-08-05	University Of Southern California	Viral chimeras comprised of CAEV and HIV-1 genetic elements
CA2331599C (en)	1998-05-12	2005-11-29	Genecure Llc	Replication defective hiv vaccine
ES2299276T3 (es) *	1998-12-31	2008-05-16	Novartis Vaccines And Diagnostics, Inc.	Polipeptidos env del vih modificados.
US7935805B1 (en)	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2487300A (en) *	1998-12-31	2000-07-31	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2000039302A2 (en)	1998-12-31	2000-07-06	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
DE60043708D1 (de) *	1999-10-13	2010-03-04	Novartis Vaccines & Diagnostic	Verfahren zur erhaltung zellimmuneantworten gegen proteinen
US8623379B2 (en) *	2000-03-02	2014-01-07	Emory University	Compositions and methods for generating an immune response
US20040105871A1 (en) *	2000-03-02	2004-06-03	Robinson Harriet L.	Compositions and methods for generating an immune response
CN1311871C (zh)	2000-03-02	2007-04-25	爱莫里大学	Dna表达载体及其应用方法
AU2001270164A1 (en) *	2000-06-26	2002-01-08	The United States Of America As Represented By The Secretary Of Agriculture	Production of vaccines using transgenic plants
JP2004522697A (ja) *	2000-09-09	2004-07-29	アクゾ・ノベル・エヌ・ベー	Ｅｉａｖキメラワクチンおよび診断
US6461616B1 (en) *	2000-09-09	2002-10-08	Akzo Nobel Nv	EIAV p26 deletion vaccine and diagnostic
US7122180B2 (en) *	2000-10-23	2006-10-17	Children's Medical Center Corporation	DNA vectors containing mutated HIV proviruses
EP1201750A1 (en)	2000-10-26	2002-05-02	Genopoietic	Synthetic viruses and uses thereof
JP4554887B2 (ja) *	2001-03-08	2010-09-29	アメリカ合衆国	改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ
EP2292772A1 (en) *	2001-07-05	2011-03-09	Novartis Vaccines and Diagnostics, Inc.	HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide
AU2002320314A1 (en)	2001-07-05	2003-01-21	Chiron, Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) *	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) *	2001-08-31	2013-04-30	Chiron Corporation	Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20050106160A1 (en) *	2002-03-05	2005-05-19	Dimitrov Dimiter S.	Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens
AU2003278496A1 (en) *	2002-11-14	2004-06-03	Pfizer Products Inc.	Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
EP1989326A4 (en)	2006-01-17	2009-09-30	Health Research Inc	BIO-HETERODUPLEX TRACKING TEST
WO2009009215A2 (en) *	2007-05-02	2009-01-15	Emory University	Enhancement of glycoprotein incorporation into virus-like particles
EP2550362B1 (en)	2010-03-25	2017-01-04	Oregon Health&Science University	Cmv glycoproteins and recombinant vectors
CA2832109C (en)	2011-06-10	2021-07-06	Oregon Health & Science University	Cmv glycoproteins and recombinant vectors
EP2568289A3 (en)	2011-09-12	2013-04-03	International AIDS Vaccine Initiative	Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en)	2011-10-27	2016-08-02	International Aids Vaccine Initiative	Viral particles derived from an enveloped virus
EP2679596B1 (en)	2012-06-27	2017-04-12	International Aids Vaccine Initiative	HIV-1 env glycoprotein variant
EP2848937A1 (en)	2013-09-05	2015-03-18	International Aids Vaccine Initiative	Methods of identifying novel HIV-1 immunogens
US10058604B2 (en)	2013-10-07	2018-08-28	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en)	2015-03-20	2017-03-15	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en)	2015-03-23	2016-09-28	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5352449A (en) *	1986-05-30	1994-10-04	Cambridge Biotech Corporation	Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
GB8923123D0 (en) *	1989-10-13	1989-11-29	Connaught Lab	A vaccine for human immunodeficiency virus
JPH05501201A (ja) *	1989-10-16	1993-03-11	ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ	非感染性ｈｉｖ―１粒子およびそれらの使用
WO1991007425A1 (en) *	1989-11-20	1991-05-30	Oncogen Limited Partnership	Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
WO1991019803A1 (en) *	1990-06-19	1991-12-26	Applied Biotechnology, Incorporated	Self assembled, defective, nonself-propagating viral particles
WO1993020220A1 (en) *	1992-03-27	1993-10-14	Whitehead Institute For Biomedical Research	Non-infectious hiv particles and uses therefor
AU4685293A (en) *	1992-07-20	1994-02-14	Immune Response Corporation, The	Prophylactic and therapeutic control of retroviral infections
GB9412844D0 (en) *	1994-06-27	1994-08-17	Medical Res Council	Improvements in or relating to therapeutic methods

1994
- 1994-08-15 US US08/290,105 patent/US5955342A/en not_active Expired - Lifetime
1995
- 1995-06-06 US US08/470,419 patent/US5866320A/en not_active Expired - Lifetime
- 1995-08-15 PT PT95927611T patent/PT778888E/pt unknown
- 1995-08-15 ES ES95927611T patent/ES2268693T3/es not_active Expired - Lifetime
- 1995-08-15 JP JP50688396A patent/JP3871708B2/ja not_active Expired - Fee Related
- 1995-08-15 AT AT95927611T patent/ATE331026T1/de active
- 1995-08-15 MX MX9701149A patent/MX9701149A/es active IP Right Grant
- 1995-08-15 DE DE69535075T patent/DE69535075T2/de not_active Expired - Lifetime
- 1995-08-15 AU AU31599/95A patent/AU704309B2/en not_active Ceased
- 1995-08-15 US US08/776,949 patent/US6025125A/en not_active Expired - Lifetime
- 1995-08-15 WO PCT/CA1995/000483 patent/WO1996005292A1/en not_active Ceased
- 1995-08-15 DK DK95927611T patent/DK0778888T3/da active
- 1995-08-15 EP EP95927611A patent/EP0778888B1/en not_active Expired - Lifetime
- 1995-08-15 CA CA002197446A patent/CA2197446A1/en not_active Abandoned
1996
- 1996-12-06 US US08/761,209 patent/US5889176A/en not_active Expired - Lifetime
- 1996-12-06 US US08/761,828 patent/US5879925A/en not_active Expired - Lifetime
2005
- 2005-07-21 JP JP2005211860A patent/JP2006020635A/ja active Pending

Also Published As

Publication number	Publication date
EP0778888A1 (en)	1997-06-18
US5879925A (en)	1999-03-09
CA2197446A1 (en)	1996-02-22
JPH10503933A (ja)	1998-04-14
US5955342A (en)	1999-09-21
PT778888E (pt)	2006-11-30
US6025125A (en)	2000-02-15
ATE331026T1 (de)	2006-07-15
AU704309B2 (en)	1999-04-22
AU3159995A (en)	1996-03-07
US5866320A (en)	1999-02-02
DE69535075T2 (de)	2007-01-04
JP2006020635A (ja)	2006-01-26
JP3871708B2 (ja)	2007-01-24
MX9701149A (es)	1997-05-31
WO1996005292A1 (en)	1996-02-22
US5889176A (en)	1999-03-30
ES2268693T3 (es)	2007-03-16
EP0778888B1 (en)	2006-06-21
DE69535075D1 (de)	2006-08-03

Publication	Publication Date	Title
DK0778888T3 (da)	2006-10-23	Antigen-mærket ikke-infektiös retroviruslignende partikel
Osterhaus et al.	1985	Induction of protective immune response in cats by vaccination with feline leukemia virus iscom.
Gherardi et al.	2003	Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes
Lai et al.	2011	Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine
WO2002020554A3 (en)	2002-06-13	Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines
US6544752B1 (en)	2003-04-08	Anigenically-marked non-infectious retrovirus-like particles
DE69535757D1 (de)	2008-07-03	Rekombinanter immunschwächepoxvirus
SE8701413L (sv)	1987-10-05	Expression och rening av en htlv-iii gag/env-gen protein
ES2307496T4 (es)	2015-03-06	Composiciones de vacuna, antígenos y péptidos de VIH
ATE154610T1 (de)	1997-07-15	Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
Alves et al.	2017	Evaluation of Plasmodium vivax cell-traversal protein for ookinetes and sporozoites as a preerythrocytic P. vivax vaccine
EP0433242A1 (en)	1991-06-19	Vaccines and process for their preparation
ATE36956T1 (de)	1988-09-15	Verfahren zu herstellung von lebenden, adjuvierten impfstoffen und so erhaltende lebende, adjuvierte impfstoffe.
ES2066887T3 (es)	1995-03-16	Anticuerpo monoclonal para diferenciar individuos seropositivos hiv-2 de los hiv-1.
Verrier et al.	2000	A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
DK0880360T3 (da)	2003-01-27	Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop
Forsell et al.	2005	Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus
EA200300335A1 (ru)	2003-08-28	Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
Merza et al.	1989	Bovine leukaemia virus ISCOMs: biochemical characterization
Chang et al.	1999	Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes
FI95871B (fi)	1995-12-29	Menetelmä HIV-hiukkasimmunogeenin ja sen vasta-aineen valmistamiseksi
Åkerblom et al.	1989	Formation and characterization of FeLV ISCOMs
Hu et al.	1993	Protection of vaccinia‐primed macaques against SIVmne infection by combination immunization with recombinant vaccinia virus and SIVmne gp160
Camp et al.	2021	Invaplex functions as an intranasal adjuvant for subunit and DNA vaccines co-delivered in the nasal cavity of nonhuman primates
KR960705919A (ko)	1996-11-08	제릴-린(jeryl-lynn) 바이러스 균주를 함유하는 유행성 귀밑샘염에 대한 백신(vaccine against mumps containing a jeryl-lynn virus strain)